Riskpilot← Back to searchSign inGet full accessSPECIFIC PHARMA A/S
A/SActiveCVR 33161395Borgmester Christiansens Gade 40Wholesale of pharmaceutical and medical goods · NACE 4646Est. 201043 employees
Revenue 2025
DKK 219,3M
+4% vs 2024
EBITDA margin
16.7%
+26% vs 2024
Equity ratio
82.7%
Financial strength
Net profit 2025
DKK 29,2M
+14% vs 2024
| Revenue | DKK 219,3M | +4% |
| EBITDA | DKK 36,5M | +26% |
| Net profit | DKK 29,2M | +14% |
| Total assets | DKK 134,5M | +7% |
| Equity | DKK 111,2M | +5% |
| Employees | 43 | — |
Legal name
SPECIFIC PHARMA A/S
CVR number
33161395
Legal form
Aktieselskab
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
15. september 2010
Share capital
DKK 5.000.000
Employees
43 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2025-01-31
Financial year
January – December
Signatory rights
Selskabet tegnes af bestyrelsens formand i forening med et andet bestyrelsesmedlem eller en direktør eller af den samlede bestyrelse.
Company purpose
Selskabets formål er - direkte eller via besiddelse af kapitalandele i andre selskaber - at drive handel med og tilbyde serviceydelser inden for sundhedsområdet samt anden virksomhed, der efter bestyrelsens skøn er forbundet dermed.
Address
Borgmester Christiansens Gade 40
Email
csc@nomeco.dk
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 60.117 | 137.766 | 132.005 | 141.067 | 142.444 | 145.726 | 146.427 | 128.248 | 139.630 | 123.270 | 177.609 | 210.987 | 219.329 |
| Staff expenses | -2.806 | -5.543 | -4.406 | -7.375 | -8.778 | -9.716 | -12.710 | -14.636 | -15.042 | -15.900 | -17.328 | -19.602 | -20.739 |
| EBITDA | 14.021 | 24.717 | 31.538 | 25 | 33.085 | 20.020 | 12.600 | 12.370 | 17.499 | 10.482 | 17.411 | 28.945 | 36.536 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -764 | -861 | -868 | -739 | -166 | -133 |
| EBIT | 14.021 | 24.717 | 31.538 | 25 | 33.085 | 20.020 | 12.600 | 11.606 | 16.638 | 9.614 | 16.672 | 28.779 | 36.403 |
| Net financials | 96 | 234 | 457 | 353 | 571 | -1.007 | -1.140 | -1.032 | 2.338 | 354 | -4.005 | 3.998 | 1.091 |
| Profit before tax | 14.117 | 24.951 | 31.995 | 26.423 | 33.656 | 19.013 | 11.460 | 10.574 | 18.976 | 9.968 | 12.667 | 32.777 | 37.494 |
| Tax | 3.529 | 6.238 | 7.864 | 6.230 | 7.416 | 4.192 | 2.546 | 2.337 | 4.177 | 2.199 | 2.791 | 7.217 | 8.255 |
| Net profit | 10.588 | 18.713 | 24.131 | 20.193 | 26.240 | 14.821 | 8.914 | 8.237 | 14.799 | 7.769 | 9.876 | 25.560 | 29.239 |
| Item | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 24.455 | 52.521 | 96.800 | 82.561 | 100.174 | 87.351 | 93.125 | 95.307 | 107.235 | 103.079 | 104.981 | 126.169 | 134.475 |
| Equity | 18.586 | 37.299 | 61.430 | 63.523 | 74.613 | 69.734 | 78.648 | 80.199 | 88.820 | 85.488 | 89.564 | 106.245 | 111.203 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | -18 | -38 | 3.324 | 3.220 | 1.742 | 98 | 198 | 127 |
| Short-term debt | 5.868 | 15.222 | 35.370 | 19.038 | 25.561 | 17.617 | 14.477 | 11.747 | 15.167 | 15.845 | 15.311 | 19.709 | 23.108 |
| Total debt | 5.868 | 15.222 | 35.370 | 19.038 | 25.561 | 17.617 | 14.477 | 15.071 | 18.387 | 17.587 | 15.409 | 19.907 | 23.235 |
EBITDA margin
16.7%
This company
15.8%
Market median
+6% vs market
20132025
Equity ratio
82.7%
This company
38.2%
Market median
+116% vs market
20132025
Return on equity
26.3%
This company
18.4%
Market median
+43% vs market
20132025
Net profit margin
13.3%
This company
8.1%
Market median
+64% vs market
20132025
Asset turnover
1.63×
This company
1.12×
Market median
+46% vs market
20132025
Debt / equity
0.21×
This company
0.62×
Market median
+66% vs market
20132025
- Annual report 2025Filed via CVR / Virk · Period 2024-02-01 – 2025-01-31
- Annual report 2024Filed via CVR / Virk · Period 2023-02-01 – 2024-01-31
- Annual report 2023Filed via CVR / Virk · Period 2022-02-01 – 2023-01-31
- Annual report 2022Filed via CVR / Virk · Period 2021-02-01 – 2022-01-31
- Annual report 2021Filed via CVR / Virk · Period 2020-02-01 – 2021-01-31
- Annual report 2020Filed via CVR / Virk · Period 2019-02-01 – 2020-01-31
- Annual report 2019Filed via CVR / Virk · Period 2018-02-01 – 2019-01-31
- Annual report 2018Filed via CVR / Virk · Period 2017-02-01 – 2018-01-31
- Annual report 2017Filed via CVR / Virk · Period 2016-02-01 – 2017-01-31
- Annual report 2016Filed via CVR / Virk · Period 2015-02-01 – 2016-01-31
- Annual report 2015Filed via CVR / Virk · Period 2014-02-01 – 2015-01-31
- Annual report 2014Filed via CVR / Virk · Period 2013-02-01 – 2014-01-31
- Annual report 2013Filed via CVR / Virk · Period 2012-02-01 – 2013-01-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
SS Chief Executive Officer | Chief Executive Officer | 2014 | — | — |
SV Deputy | Deputy | 2014 | — | — |
OM Chief Executive Officer | Chief Executive Officer | 2019 | — | — |
UK Chief Executive Officer | Chief Executive Officer | 2019 | — | — |
UB Chief Executive Officer | Chief Executive Officer | 2010 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2014 | — | — | |
| Chairman | 2010 | — | — | |
| Chairman | 2026 | — | — | |
| Board of Directors | 2011 | — | — | |
| Board of Directors | 2026 | — | — | |
| Board of Directors | 2019 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
NOMECO A/S | Company | 100.0% | 100.0% | 2014 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
PHOENIX DANISH HOLDING A/S
SPECIFIC PHARMA A/S Board members of SPECIFIC PHARMA A/S also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Samia Sofie Kappe | Chief Executive Officer | 0 companies |
| Søren Vesti Esbensen | Deputy | 0 companies |
| Ole Markussen | Chief Executive Officer | 0 companies |
| Uffe Kåre Jensen | Chief Executive Officer | 0 companies |
| Ulf Blangsted Henriksen | Chief Executive Officer | 0 companies |
| Pia Rask Stewart | Board of Directors | 0 companies |
| Per Bornhøft Hansen | Board of Directors | 0 companies |
| Jan Bonde | Chairman | 0 companies |
| Kristine Sakstrup Haag | Chairman | 0 companies |
| Tina Majgård Moltke-Leth | Board of Directors | 0 companies |
| Henrik Kaastrup | Board of Directors | 0 companies |
| Ken Rasmussen | Board of Directors | 0 companies |